axsome

migraine treatment optimization questionnaire-4 (mTOQ-4)

Determines effectiveness of current migraine treatment plan.¹

This tool can be used to gauge symptom control of acute migraine therapy, and is included by the American Headache Society as a tool to assess treatment response.²

| After taking your migraine medication, are you pain-free within 2 hours for most attacks? | Never or rarely | 0 |
|--|--------------------------|----|
| | Less than half the time | +1 |
| | Half the time or greater | +2 |
| Does 1 dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours? | Never or rarely | 0 |
| | Less than half the time | +1 |
| | Half the time or greater | +2 |
| Are you comfortable enough with your migraine medication to be able to plan your daily activities? | Never or rarely | 0 |
| | Less than half the time | +1 |
| | Half the time or greater | +2 |
| After taking your migraine medication, do you feel in control of your migraines enough so that you feel you can return to normal function? | Never or rarely | 0 |
| | Less than half the time | +1 |
| | Half the time or greater | +2 |

Treatment efficacy:

0 = Very Poor, 1-5 = Poor, 6-7 = Moderate, 8 = Maximum

mTOQ-4 score =

Is your patient's score less than 8?

Discuss alternative treatment options.

References: 1. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688-695. doi:10.1212/WNL.00000000001256. 2. Ailani J, Burch R, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;6(7):1021–1039. doi:10.1111/head.14153

AXSOME and its logos are registered trademarks of Axsome Therapeutics, Inc. ©2025 Axsome Therapeutics, Inc. All rights reserved. PP-MIG-US-2500024 05/2025